Biblio
Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study. Front Oncol. 2023;13:1208028.
. Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. J Hematol Oncol. 2023;16(1):96.